Physician profile
Michael Russell
NPI 1023336039
$23,542.65
in general payments reported to CMS, 2019-2025
71 companies · $3,415 in 2025
The $3,415 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,167 · 2020: $3,459 · 2021: $4,262 · 2022: $3,455 · 2023: $3,016 · 2024: $2,769 · 2025: $3,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,152 · Education: $47.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,152.29 |
| Education | $47.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,136.48 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $2,077.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,840.46 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $1,643.74 | 2019-2025 | |
| Lilly USA, LLC | $1,634.87 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $1,634.17 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Amgen INC. | $1,423.61 | 2019-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $1,215.16 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,003.43 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $699.11 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $494.38 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $452.05 | 2022-2025 | |
| Allergan, INC. | $439.52 | 2019-2020 | |
| Astellas Pharma US INC | $430.44 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $430.26 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.